[HTML] sciencedirect.com

[HTML][HTML] Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

SP Aix, AC Toffart - ESMO open, 2023 - Elsevier
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …
被引用次数：11 相关文章

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, S Cedres, T Berghmans… - ESMO …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, S Cedres, T Berghmans… - ESMO …, 2023 - cris.maastrichtuniversity.nl
Background: Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …
[PDF] researchgate.net

[PDF][PDF] Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, S Cedres, T Berghmans, S Burgers… - researchgate.net
Background: Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

N Girard, S Cedres, T Berghmans, S Burgers… - ESMO Open, 2023 - europepmc.org
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, SM Cedres, T Berghmans… - ESMO Open, 2023 - hal.science
Background: Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …

[引用][C] Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.

N Girard, S Ponce Aix, S Cedres, T Berghmans… - ESMO …, 2023 - difusion.ulb.ac.be

Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, S Ponce Aix, S Cedres, T Berghmans… - ESMO OPEN, 2023 - air.unipr.it
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …
[HTML] nih.gov

[HTML][HTML] Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, S Cedres, T Berghmans, S Burgers… - ESMO Open, 2023 - ncbi.nlm.nih.gov
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …
[PDF] uantwerpen.be

[PDF][PDF] Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial

N Girard, SP Aix, S Cedres, T Berghmans, S Burgers… - repository.uantwerpen.be
Background: Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic …